Nova Patents
AT288261T

Regulation of intracellular glucocorticoid concentrations

Abstract

Interconversion of 11 US EQUIVALENTS 11 BE} IANTE USE OF INHIBITORS OF THE ENZYME 11 BE} TO AS carbenoxolone (ACID 3 BE} EDEN USED IN ONE OF USES THERAPEUTIC IN HUMAN ANIMALS SERIES, for example to inhibit gluconeogenesis LIVER TO Cortisol levels DECREASE intracellular TO INCREASE iNSULIN SENSITIVITY AND mUSCLE adipose tissue, and prevent or reduce loss NEURONAL / COGNITIVE DECREASE DUE TO INJURY OR DYSFUNCTION NEURAL neurotoxicity powered by glucocorticoids.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

30 members in 10 offices

This recordMember, by publication datePriority claim

Priority claims2

Priority claims
DocumentOfficeKindDate
9517622United KingdomA
9602134United KingdomW

Members30

Family members, oldest first
DocumentOfficeKind
GB9517622D0United KingdomD0
WO9707789A1World Intellectual Property Organization (WIPO)A1
AU6833796AAustraliaA
GB9801921D0United KingdomD0
GB2317826AUnited KingdomA
EP0847275A1European Patent Office (EPO)A1
GB2317826BUnited KingdomB
US2001039294A1United States of AmericaA1
US6368816B2United States of AmericaB2
US2002076781A1United States of AmericaA1
US2002128244A1United States of AmericaA1
US2002128245A1United States of AmericaA1
US2002128246A1United States of AmericaA1
US2003069216A1United States of AmericaA1
US2003078244A1United States of AmericaA1
EP1464337A1European Patent Office (EPO)A1
US6838253B2United States of AmericaB2
EP0847275B1European Patent Office (EPO)B1
AT288261TThis recordAustriaT
ATE288261T1AustriaT1
DE69634299D1GermanyD1
DK0847275T3DenmarkT3
PT847275EPortugalE
DE69634299T2GermanyT2
ES2235194T3SpainT3
US6946487B2United States of AmericaB2
US7087400B2United States of AmericaB2
US7122531B2United States of AmericaB2
US7122532B2United States of AmericaB2
US7129231B2United States of AmericaB2